Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009.
J Clin Endocrinol Metab. 2010 Mar;95(3):1095-104. doi: 10.1210/jc.2009-1977. Epub 2010 Jan 22.
Longitudinal studies of risk factors for hypothyroidism are required to inform debate regarding the TSH reference range. There are limited longitudinal data on the predictive value of thyroid antibodies measured by automated immunoassay (as opposed to semiquantitative methods).
We measured TSH, free T(4), thyroid peroxidase antibodies (TPOAbs), and thyroglobulin antibodies (TgAbs) using the Immulite platform on sera from 1184 participants in the 1981 and 1994 Busselton Health Surveys. Outcome measures at follow-up were hypothyroidism, defined as TSH greater than 4.0 mU/liter or on thyroxine treatment; and overt hypothyroidism, defined as TSH above 10.0 mU/liter or on thyroxine treatment. Receiver-operator characteristic analysis was used to determine optimal cutoffs for baseline TSH, TPOAbs, and TgAbs as predictors of hypothyroidism.
At 13 yr follow-up, 110 subjects (84 women) had hypothyroidism, of whom 42 (38 women) had overt hypothyroidism. Optimal cutoffs for predicting hypothyroidism were baseline TSH above 2.5 mU/liter, TPOAbs above 29 kIU/liter, and TgAbs above 22 kIU/liter, compared with reference range upper limits of 4.0 mU/liter, 35 kIU/liter, and 55 kIU/liter, respectively. In women with positive thyroid antibodies (TPOAbs or TgAbs), the prevalence of hypothyroidism at follow-up (with 95% confidence intervals) was 12.0% (3.0-21.0%) when baseline TSH was 2.5 mU/liter or less, 55.2% (37.1-73.3%) for TSH between 2.5 and 4.0 mU/liter, and 85.7% (74.1-97.3%) for TSH above 4.0 mU/liter.
The use of TSH cutoffs of 2.5 and 4.0 mU/liter, combined with thyroid antibodies, provides a clinically useful estimate of the long-term risk of hypothyroidism.
为了为 TSH 参考范围的争论提供信息,需要进行甲状腺功能减退症危险因素的纵向研究。关于使用自动化免疫分析(而非半定量方法)测量的甲状腺抗体的预测价值,纵向数据有限。
我们使用 Immulite 平台,对 1981 年和 1994 年布塞尔顿健康调查中 1184 名参与者的血清中的 TSH、游离 T(4)、甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体(TgAb)进行了测量。随访时的结局是甲状腺功能减退症,定义为 TSH 大于 4.0 mU/L 或正在服用甲状腺素;显性甲状腺功能减退症,定义为 TSH 高于 10.0 mU/L 或正在服用甲状腺素。使用受试者工作特征曲线分析确定 TSH、TPOAb 和 TgAb 作为甲状腺功能减退症预测指标的最佳截断值。
在 13 年的随访中,110 名受试者(84 名女性)患有甲状腺功能减退症,其中 42 名(38 名女性)患有显性甲状腺功能减退症。与 TSH 参考范围上限 4.0 mU/L、35 kIU/L 和 55 kIU/L 相比,预测甲状腺功能减退症的最佳截断值分别为 TSH 基线值高于 2.5 mU/L、TPOAb 高于 29 kIU/L 和 TgAb 高于 22 kIU/L。在甲状腺抗体(TPOAb 或 TgAb)阳性的女性中,当 TSH 基线值为 2.5 mU/L 或更低时,随访时甲状腺功能减退症的患病率(95%置信区间)为 12.0%(3.0-21.0%);当 TSH 为 2.5-4.0 mU/L 时,为 55.2%(37.1-73.3%);当 TSH 大于 4.0 mU/L 时,为 85.7%(74.1-97.3%)。
使用 TSH 截断值 2.5 和 4.0 mU/L,结合甲状腺抗体,可对甲状腺功能减退症的长期风险进行临床有用的估计。